Stocks Health care ADIL
NASDAQ · Health careAdial Pharmaceuticals, Inc. (ADIL)
It posted a net loss of $57.8M. At June 30, 2026 it held $28.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Adial Pharmaceuticals, Inc.
- Net worth
- Adial Pharmaceuticals, Inc. has a market value (market cap) of $13.3M at the latest share price, and shareholders' equity of -$38.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $6.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Adial Pharmaceuticals, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Adial Pharmaceuticals, Inc. does
Adial Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ADIL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$8M | -$11.93 | n/a |
| 2024 | n/a | -$13.2M | -$68.01 | n/a |
| 2023 | n/a | -$5.1M | -$90.01 | n/a |
| 2022 | n/a | -$12.7M | -$317.80 | n/a |
| 2021 | n/a | -$19.4M | -$648.06 | -$12M |
| 2020 | n/a | -$10.9M | -$542.12 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Adial Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Additional proxy material DEFA14A
- October 2, 2026Other event 8-K
- September 18, 2026Additional proxy material DEFA14A
- September 18, 2026Executive or director change8-KAdial Pharmaceuticals held its 2026 annual meeting, approving an increase in authorized shares and equity plans while adjourning four proposals pending Nasdaq review.
- September 16, 2026Additional proxy material DEFA14A
- September 16, 2026
- August 28, 2026
- August 28, 2026
- August 25, 2026
- August 24, 2026
Insider trades
What the people running Adial Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 16, 2026 | Coastlands Capital LP10% owner | Boughtindirect | 1,233 | $3.4K |
| July 14, 2026 | Coastlands Capital LP10% owner | Boughtindirect | 2,000 | $5.3K |
| July 10, 2026 | Coastlands Capital LP10% owner | Boughtindirect | 1,700 | $4.6K |
| July 9, 2026 | Coastlands Capital LP10% owner | Boughtindirect | 10,053 | $28K |
| June 29, 2026 | Coastlands Capital LP10% owner | Boughtindirect | 25,000 | $65K |
| June 12, 2026 | Davidson MattChief Development Officer, Director | Received as pay | 232,417 | - |
| June 11, 2026 | Davidson MattChief Development Officer, Director | Received as pay | 61,647 | - |
| June 11, 2026 | Davidson MattChief Development Officer, Director | Received as payindirect | 3,427 | - |
Who owns ADIL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Coastlands Capital LP13G, passive with 4 related filers | 14.22% | July 1, 2026 |
Largest institutional holders
Insiders
7 insiders reported holding 795,635 shares in total, about $4M at the last price.
| Holder | Shares |
|---|---|
| Coastlands Capital LP10% owner | 388,308388,308 held indirectly |
| Davidson MattChief Development Officer, Director | 304,6645,350 held indirectly |
| Claiborne Cary JChief Executive Officer, Director | 40,417 |
| Goodman TonyChief Operating Officer, Director | 26,523 |
| Shah VinayChief Financial Officer | 17,325 |
| Schuyler KevinDirector | 9,213 |
| Gilliland Robertson H.Director | 9,185 |
Questions about ADIL
What does Adial Pharmaceuticals, Inc. do?
Adial Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ADIL. Its shares trade on NASDAQ under the ticker ADIL.
What is Adial Pharmaceuticals, Inc.'s net worth?
Adial Pharmaceuticals, Inc. has a market value (market cap) of $13.3M at the latest share price, and shareholders' equity of -$38.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Adial Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $57.8M.
When did Adial Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the additional proxy material from October 5, 2026.
When is Adial Pharmaceuticals, Inc.'s next earnings report?
Adial Pharmaceuticals, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ADIL with
Follow ADIL
Get an email when Adial Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Adial Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.